Log In
Print
BCIQ
Print
Print this Print this
 

danoprevir (ASC-08, ITMN-191, RG7227) (formerly R7227)

Also known as: formerly ITMN B

  Manage Alerts
Collapse Summary General Information
Company Roche
DescriptionHCV NS3/4A protease inhibitor
Molecular Target HCV NS3/4A protease complex
Mechanism of ActionViral protease inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV genotype 1 infection; Treat HCV genotype 1 infection; Treat HCV genotype 1 infection in patients who failed previous therapy; Treat HCV infection
Regulatory Designation

Partner

Ascletis Pharmaceuticals Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today